build better fxr luck
upgrad outperform base view increasingli like
first-in-class potenti best-in-class fxr agonist nash came
away aasld percept oca like achiev stat sig
primari endpoint regener oca-associ pruritu like
minim titrat nash patient oca-associ ldl-
 increas manag statin next-gener fxr agonist
unlik elimin pruritu ldl-c increas base observ
increas probabl success oca nash drive pt
rate outperform detail
encourag reanalysi flint data present aasld use
regenerate-match complet popul nash resolut
estim likelihood success regener confid
nash resolut fibrosi latter slightli riskier assum efficaci
outcom replic approxim effect size flint margin
error exhibit
expect titrat titrat regener minim
pruritu base success titrat pbc rel low
rate pruritu vs pbo control also believ slight
elev ldl-c caus oca like control low-dos statin
demonstr control exhibit
expert suggest fxr mechan valid oca fast follow
tri improv profil limit success exampl includ
txr exhibit addit seek enhanc efficaci via greater
potenc fast follow also aim less pruritu expert indic could
imposs elimin could potenti reduc lower dose
pbc ocaliva script still grow albeit slowli assum
ocaliva price gravit toward nash price base share dose
reason pbc minor contributor hypothet sotp
valuat although provid estim floor along psc
event regener fail exhibit
could go wrong highlight concern sever long-term risk
includ patent price reimburs believ oca
patent protect point transit busi
potent consid estim net annual
price oca roughli align real-world econom outcom studi
compani focus develop
novel treatment liver diseas
analyst certif import disclosur see disclosur
nash phase trial move forward investor mostli skeptic
outcom
pbc sale slightli consensu
 specul driven nash competit dynam
investor becom comfort risk/reward around nash
pbc sale robust consensu
believ lead asset obetichol acid oca
approv treatment primari biliari cholang pbc
late-stag develop treatment nonalcohol
steatohepat nash addit indic well-
defin clinic benefit overal risk/reward profil
appear highli favor like becom first-in-class
treatment nash
commerci ramp oca pbc
continu eu launch oca pbc
potenti complet enrol regener opco
interim data regener
ocaliva launch slower anticip and/or reimburs low
phase nash regener trial fail meet primari endpoint
pt base dcf valuat wacc termin valu growth rate hypothet sotp valuat
includ pbc nash minim contribut psc although valuat methodolog use
pt
risk includ clinic trial risk pivot us phase nash trial studi competit risk commerci risk pbc
sale fail meet expect
exhibit updat flint subset analysi regenerate-lik patient show efficaci
exhibit estim po two primari endpoint regener believ regener
like deliv endpoint placebo correct differ nash resolut fibrosi
improv match differ observ regenerate-lik popul flint
pe na improv nash resolut lancet nash resolut exclud bl nashpati aasld estim flint nash resolut addit na improv requir flint regener -like subsetanalysi nash resolutionw/o worsen patient aasld nash resolut fibrosi improv lancet fibrosi improv aasld flint regener -like subset analysi fibrosi improv w/o nash worsen patient aasld fibrosi improv resolut endpointprimari endpoint hypothet nash resolut improv endpointprimari endpoint hypothet fibrosi improv intercept pharmaceut
exhibit control result dose show potenti titrat regimen
exhibit ldl-c show slight elev flint nash patient like control low-
dose statin demonstr control
exhibit ldl-c show slight elev flint nash patient like control low-
dose statin demonstr control
exhibit fxr mechan valid oca fast follow tri improv profil
reduc liver fat measur mri-pdff reduct fibrosi marker
mri respond still level pruritu
exhibit fxr mechan valid oca fast follow tri improv profil
tropixefor txr reduc liver fat measur mri-pdff reduct biomark
still level pruritu elev
exhibit pbc script fallen short earlier expect still grow slowli
longer signific contributor valuat estim
oppenheim co
exhibit hypothet sotp valuat includ pbc psc nash
exhibit hypothet sotp valuat goe nash fail establish floor
weekli weekli weekli weekli actualdrug/indicationexpect launchpeak sale estim mm estimate probabl successnon-probabiliy adj npvp-adj npv mm p-adj valu shareoca primari biliari primari scleros equiti share outstand use valuat oppenheim co drug/indicationexpect launchpeak sale estim mm estimate probabl successnon-probabiliy adj npvp-adj npv mm p-adj valu shareoca primari biliari primari scleros equiti share outstand use valuat oppenheim co intercept
exhibit dcf valuat methodolog support pt
intercept dcfdiscount analysi except per-shar data mn except per-shar data revenu growth chang work work capit valu growth valu oppenheim co equiti valu per sharetermin valu growth rate outperform
us nash popul nash popul growth treat nash popul nash nash without fibrosi fibrosi compens cirrhosi decompens cirrhosi ratesnash without fibrosi fibrosi compens cirrhosi nash without fibrosi nash fibrosi nash fibrosi nash compens cirrhosi fibrosi oca nash fibrosi price nash fibrosi us oca sale nash popul vs patient nash without patient nash patient nash compens penetrationnash without fibrosi fibrosi oca nash fibrosi price nash fibrosi eu oca sale ww oca sale intercept pharmaceut
probabl success
probabl success
probabl success
licens revenu mileston
good
research develop
adjust research develop non-gaap
share-bas compens
total share-bas compens
sell gener administr
adjust sell gener administr non-gaap
share-bas compens sg
total share-bas compens
total share-bas compens exclud non-gaap op
depreci exclud non-gaap op ex
interest dividend incom
revalu warrant
gaap ep basic dilut
equival
